Authors:
SL Cooke, JD Brenton
Journal name: 
Lancet Oncol
Citation info: 
12(12):1169-1174
Abstract: 
High-grade serous ovarian cancers account for most ovarian-cancer mortality. Although this disease initially responds well to platinum-based chemotherapy, relapse and progression to chemotherapy resistance are frequently seen. Time to relapse after first-line therapy is a predictor of response to secondary platinum treatment: more than 12 months is associated with high chance of a secondary response, whereas relapses within 6 months generally indicate platinum resistance. In this Personal View we discuss whether patterns of response, relapse, and the development of drug resistance in high-grade serous ovarian cancers are related to distinct underlying molecular and cellular biological characteristics. In particular, we propose that rapid relapse with platinum-resistant disease is due to minor subpopulations of intrinsically resistant cancer cells at presentation.
DOI: 
http://doi.org/10.1016/S1470-2045(11)70123-1
Research group: 
Brenton Group
E-pub date: 
01 Nov 2011